Bleomycin



Bleomycin
Systematic (IUPAC) name
rel-(3-{[(2'-{(5R,8R,9R,10S,13R)-15-{6-Amino-2-

[(1R)-3-amino-1-{[(2R)-2,3-diamino-3-oxopropyl] amino}-3-oxopropyl]-5-methyl-4-pyrimidinyl}-13- [{[(2S,3R,4R,5R,6R)-3-{[(2S,3R,4R,5S,6S)-4- (carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl) tetrahydro-2H-pyran-2-yl]oxy}-4,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} (1H-imidazol-5-yl)methyl]-9-hydroxy-5- [(1S)-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15- tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'- bi-1,3-thiazol-4-yl)carbonyl]amino}propyl) (dimethyl)sulfonium

Identifiers
CAS number 11056-06-7
ATC code L01DC01
PubChem 456190
DrugBank APRD00453
Chemical data
S3 
Mol. mass 1415.56
Pharmacokinetic data
Bioavailability well absorbed
Metabolism  ?
Half life 2 hours
Excretion renal (60-70%)
Therapeutic considerations
Pregnancy cat.

D(US)

Legal status

?

Routes intramuscular and subcutaneous

Bleomycin is a regimen), squamous cell carcinomas, and testicular cancer, pleurodesis as well as plantar warts.

History

See also: History of cancer chemotherapy

Bleomycin was first discovered in 1962 when the Japanese scientist Hamao Umezawa found anti-cancer activity while screening culture filtrates of S. verticullus. Umezawa published his discovery in 1966. The drug was launched in Japan by Nippon Kayaku in 1969. In the US bleomycin gained Bristol-Myers Squibb precursor Bristol Laboratories under the brand name Blenoxane.

Suppliers

Bristol-Myers Squibb still supplies Blenoxane. There are also generic versions of bleomycin available from Bedford, Sicor (Teva) and Mayne Pharma.

Mechanism of action

Bleomycin acts by induction of lipid peroxidation and oxidation of other cellular molecules.

Side effects

The most serious complication of bleomycin is pulmonary fibrosis and impaired lung function. Other side effects include fever, rash, hyperpigmentation, alopecia, Raynaud's phenomenon, Hearing Loss and ototoxicity.

See also

References

  • Claussen, C.A.; Long, E.C. (1999). "Nucleic Acid Recognition by Metal Complexes of Bleomycin". Chem. Rev. 99: 2797-2816. PMID 11749501.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bleomycin". A list of authors is available in Wikipedia.